<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060146</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-I/2019/FD-01</org_study_id>
    <nct_id>NCT05060146</nct_id>
  </id_info>
  <brief_title>Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.</brief_title>
  <acronym>OPTIVACC</acronym>
  <official_title>Prevention of Pneumococcal Infections: Impact Collaborative Medico-pharmaceutical Care Structured to Improve Vaccination Coverage of Patients at Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In France, Streptococcus pneumoniae is the leading agent bacterial involved in community lung&#xD;
      disease and meningitis. The frequency of these infections and their mortality increase&#xD;
      significantly in those at risk such as patients with certain chronic diseases,&#xD;
      immunocompromised or on immunosuppressive therapy. This population, despite regular&#xD;
      monitoring, has a limited pneumococcal vaccine coverage of around 20%. By carrying out a&#xD;
      reconciliation of treatments upon admission to hospital, the clinical pharmacist can detect&#xD;
      those without up to date pneumococcal vaccination status. The goal of this management is to&#xD;
      make the patient aware of the need for vaccination and organization upon return home. Thus,&#xD;
      this limited pneumococcal vaccination coverage would benefit from intervention by regional&#xD;
      clinical pharmacy activities. The study investigators want to study the impact of a&#xD;
      structured medico-pharmaceutical collaboration on pneumococcal vaccination of patients with&#xD;
      risk on discharge from hospital. The investigators hypothesize that this collaboration in&#xD;
      patients at risk of infection with pneumococcus could significantly increase their&#xD;
      anti-pneumococcal vaccination coverage&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Step wedge</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Full vaccination coverage (2 doses) between groups</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>Yes/No, confirmed by the administrator</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Full vaccination coverage (2 doses) between groups, stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>Yes/No, confirmed by the administrator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial vaccination coverage (1st dose only) between groups and stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>Yes/No, confirmed by the administrator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Record of both vaccines being dispensed by the pharmacy between groups and stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>6 months after last follow-up visit</time_frame>
    <description>Yes/No according to Système national d'information inter-régimes de l'Assurance maladie (SNIIRAM) database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance between vaccines dispensed and vaccines recorded in the SNIRRAM database between groups and stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>6 months after discharge</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prescription of vaccines at discharge by the doctor between groups and stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>at discharge (average 5 days after hospitlization)</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Notification of requirement for vaccine between groups and stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>at discharge (average 5 days after hospitlization)</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transmission of letter highlighting the absence of vaccination by the pharmacy to the patient's doctor between groups and stratified by type of establishment (University hospital vs hospital) and by service (Medicine vs Surgery)</measure>
    <time_frame>at discharge (average 5 days after hospitlization)</time_frame>
    <description>Yes/No</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">768</enrollment>
  <condition>Streptococcus Pneumoniae Infection</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Structured medico-pharmaceutical collaboration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Structured medico-pharmaceutical collaboration</intervention_name>
    <description>Reconciliation of drug treatments; Writing of the prescription for discharge from hospital for the pneumococcal vaccine; Pharmaceutical interview at discharge; Drafting of the discharge letter and transmission to the attending physician; Writing of the pharmaceutical discharge letter and transmission to the pharmacist; Pharmaceutical dispensing in the pharmacy; Administration of the vaccine by the attending physician or a nurse at home.</description>
    <arm_group_label>Structured medico-pharmaceutical collaboration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  The patient must have given their free and informed oral consent&#xD;
&#xD;
          -  The patient must be a member or beneficiary of a health insurance plan&#xD;
&#xD;
          -  The patient is admitted to full hospitalization in a surgical or medical department.&#xD;
&#xD;
          -  The patient will benefit from a reconciliation of drug treatments.&#xD;
&#xD;
          -  The patient is considered at risk of pneumococcal infection according to the&#xD;
             recommendations of March 2017 of the High Council of Public Health (HCSP)&#xD;
&#xD;
          -  Pneumococcal vaccination is not up to date according to the HCSP 2017 recommendations.&#xD;
&#xD;
          -  The patient will return home following discharge&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject is participating in a category 1 interventional study&#xD;
&#xD;
          -  The patient has participated in a category 1 trial within the previous 3 months or is&#xD;
             in a period of exclusion determined by a previous study&#xD;
&#xD;
          -  It is impossible to give the subject informed information&#xD;
&#xD;
          -  The patient is under safeguard of justice or state guardianship&#xD;
&#xD;
          -  The patient is not in a fit state to express consent&#xD;
&#xD;
          -  The patient is pregnant, parturient or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Florent Dubois</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nīmes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florent Dubois</last_name>
    <phone>04 66 68 38 44</phone>
    <email>florent.dubois@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CH Alès Cévennes</name>
      <address>
        <city>Alès</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Vincent Bouix</last_name>
      <phone>04 66 78 33 33</phone>
      <email>dr.bouix@ch-ales.fr</email>
    </contact>
    <investigator>
      <last_name>Vincent Bouix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Bagnols sur Cèze</name>
      <address>
        <city>Bagnols-sur-Cèze</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Montauban</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier Seree de Roch</last_name>
      <phone>05 63 92 80 94</phone>
      <email>x.sereederoch@ch-montauban.fr</email>
    </contact>
    <investigator>
      <last_name>Xavier Seree de Roch</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maxime Villiet</last_name>
      <phone>04.67.33.85.62</phone>
      <email>m-villiet@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Maxime Villiet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Florent Dubois</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-Marie Kinowski</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Geraldine Leguelinel Balche</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paul Loubet</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH de Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Isabelle Heran</last_name>
      <phone>04 68 61 66 41</phone>
      <email>isabelle.heran@ch-perpignan.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Heran</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Comminges Pyrénées</name>
      <address>
        <city>Saint-Gaudens</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie Bonnet</last_name>
      <phone>05 62 00 40 00</phone>
      <email>Julie.bonnet@ch-saintgaudens.fr</email>
    </contact>
    <investigator>
      <last_name>Julie Bonnet</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH du Bassin de Thau</name>
      <address>
        <city>Sète</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Laurent Giraudon</last_name>
      <phone>04 67 46 57 70</phone>
      <email>lgiraudon@ch-bassindethau.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Giraudon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe Cestac</last_name>
      <phone>05 61 32 28 85</phone>
      <email>cestac.p@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe Cestac</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 7, 2021</study_first_submitted>
  <study_first_submitted_qc>September 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 16, 2021</last_update_submitted>
  <last_update_submitted_qc>September 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Pneumonia, Pneumococcal</mesh_term>
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

